Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: A meta-analysis of randomized controlled clinical trials

Annals of Surgery

Volumn 258, Issue 6, 2013, Pages 922-929

  Teraa, Martin ^a   Sprengers, Ralf W ^a   Van Der Graaf, Yolanda ^b   Peters, Charmaine E J ^a   Moll, Frans L ^a   Verhaar, Marianne C ^a  

^a Department of Nephrology and Hypertension ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bone marrow derived cell therapy; Cell Therapy; CLI; critical limb ischemia; Meta Analysis; PAD; peripheral arterial disease

Indexed keywords

PLACEBO;

AMPUTATION; ANKLE BRACHIAL INDEX; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW CELL; CELL THERAPY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL (TOPIC); CRITICAL LIMB ISCHEMIA; DATA BASE; FALSE ANEURYSM; FOLLOW UP; HEMATOCRIT; HEMATOMA; HUMAN; INGUINAL REGION; MEDLINE; META ANALYSIS; OXYGEN THERAPY; PAIN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; STENT THROMBOSIS; SURVIVAL; SYSTEMATIC REVIEW; WALKING;

BONE MARROW TRANSPLANTATION; CRITICAL ILLNESS; HUMANS; ISCHEMIA; LEG; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 84888134486     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182854cf1     Document Type: Article

References (40)

1. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5-S67.
2. Becker F, Robert-Ebadi H, Ricco JB, et al. Chapter I: definitions, epidemiology, clinical presentation and prognosis. Eur J Vasc Endovasc Surg. 2011;42 (suppl 2):S4-12.
3. Sprengers RW, Teraa M, Moll FL, et al. Quality of life in patients with nooption critical limb ischemia underlines the need for new effective treatment. J Vasc Surg. 2010;52:843-849.
4. Barshes NR, Chambers JD, Cohen J, et al. Long-term cost-effectiveness in the contemporary management of critical limb ischemia with tissue loss. J Vasc Surg. 2012;56:1015.e1-1024.e1.
5. Benoit E, O'Donnell TF, Jr, Patel AN. Safety and efficacy of autologous cell therapy in critical limb ischemia: a systematic review of the literature [published online ahead of print Mar 28, 2012]. Cell Transplant. 2012. doi: 10.3727/096368912X636777.
6. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427-435.
7. Sprengers RW, Lips DJ, Moll FL, et al. Progenitor cell therapy in patients with critical limb ischemia without surgical options. Ann Surg. 2008;247:411-420.
8. Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease. Meta-analysis and systematic review of the literature. Atherosclerosis. 2010;209:10-17.
9. Benoit E, O'Donnell TF Jr, Iafrati MD, et al. The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. J Transl Med. 2011;9:165.
10. Powell RJ, Marston WA, Berceli SA, et al. Cellular therapy with ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebocontrolled RESTORE-CLI Trial. Mol Ther. 2012;20:1280-1286.
11. Walter DH, Krankenberg H, Balzer JO, et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv. 2011;4:26-37.
12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
13. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
14. Altman DG. Better reporting of randomised controlled trials: the CONSORT statement. BMJ. 1996;313:570-571.
15. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5:13.
16. Liu T, Li G, Li L, et al. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol. 2007;49:1642-1648.
17. Powell RJ, Comerota AJ, Berceli SA, et al. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. J Vasc Surg. 2011;54:1032-1041.
18. Iafrati MD, Bandyk D, Benoit E, et al. Bone marrow aspirate concentrate in critical limb ischemia: Results of a multicenter randomized double-blind trial. J Vasc Surg. 2010;52:1123.
19. Arai M, Misao Y, Nagai H, et al. Granulocyte colony-stimulating factor: a noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ J. 2006;70:1093-1098.
20. Baŕc P, Skora J, Pupka A, et al. Bone-marrow cells in therapy of critical limb ischaemia of lower extremities-Own experience. Acta Angiolog. 2006;12:155-166.
21. Dash NR, Dash SN, Routray P, et al. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res. 2009;12:359-366.
22. Debin L,Youzhao J, Ziwen L, et al.Autologous transplantation of bone marrow mesenchymal stem cells on diabetic patients with lower limb ischemia. J Med Coll PLA. 2008;23:106-115.
23. Huang P, Li S, Han M, et al. Autologous transplantation of granulocyte colonystimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care. 2005;28:2155-2160.
24. Ozturk A, Kucukardali Y, Tangi F, et al. Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia. J Diabetes Complications. 2012;26:29-33.
25. Prochazka V, Gumulec J, Jaluvka F, et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant. 2010;19:1413-1424.
26. Lu D, Chen B, Liang Z, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind, randomized, controlled trial. Diabetes Res Clin Pract. 2011;92:26-36.
27. Wen Y, Meng L, Gao Q. Autologous bone marrow cell therapy for patients with peripheral arterial disease: ameta-analysis of randomized controlled trials. Expert Opin Biol Ther. 2011;11:1581-1589.
28. Martin-Rendon E, Brunskill SJ, Hyde CJ, et al. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J. 2008;29:1807-1818.
29. Durdu S, Akar AR, Arat M, et al. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J Vasc Surg. 2006;44:732-739.
30. Lasala GP, Silva JA, Minguell JJ. Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product. J Thorac Cardiovasc Surg. 2012;144:377-382.
31. Lawall H, Bramlage P, Amann B. Stem cell and progenitor cell therapy in peripheral artery disease: a critical appraisal. Thromb Haemost. 2010;103:696-709.
32. Wen Z, Zheng S, Zhou C, et al. Repairmechanisms of bone marrow mesenchymal stem cells in myocardial infarction. J Cell Mol Med. 2011;15:1032-1043.
33. Huang PP,Yang XF, Li SZ, et al.Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost. 2007;98:1335-1342.
34. Onodera R, Teramukai S, Tanaka S, et al. Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis. Bone Marrow Transplant. 2011;46:278-284.
35. Gu YQ, Zhang J, Guo LR, et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chin Med J (Engl). 2008;121:963-967.
36. Van Tongeren RB, Hamming JF, Fibbe WE, et al. Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. J Cardiovasc Surg (Torino). 2008;49:51-58.
37. Klepanec A, Vulev I, Mistri K, et al. Randomized comparison of intra-arterial and intramuscular mesenchymal stem cells therapy in patients with critical limb ischemia: 3-month results. Am J Roentgenol. 2011;196:A284.
38. Idei N, Soga J, Hata T, et al. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Interv. 2011;4:15-25.
39. De VrieseAS, Billiet J,Van Droogenbroeck J, et al.Autologous transplantation of bone marrowmononuclear cells for limb ischemia in a Caucasian population with atherosclerosis obliterans. J Intern Med. 2008;263:395-403.
40. Heiss C, Keymel S, Niesler U, et al. Impaired progenitor cell activity in agerelated endothelial dysfunction. J Am Coll Cardiol. 2005;45:1441-1448.